Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director Nov 1, 2023
Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents Sep 27, 2023
Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium Aug 28, 2023
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update Aug 11, 2023
Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August Aug 8, 2023
Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit Jul 26, 2023